- Breast
- Lung
- Hematologic Oncology
- Gastrointestinal
- Genitourinary
- General Oncology
- Sarcoma
- Skin
- Head & Neck
- Event
Playback speed
10 seconds
New Drugs Have an Established Role in CLL: BCR and BCL2 Inhibitors (Ibrutinib, Idelalisib / Rituximab, Venetoclax +/- Rituximab), New Agents Combos, and Their Effect on OS and PFS
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Robin Foa
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Robin Foa
211 views
December 20, 2019
Comments 0
Login to view comments.
Click here to Login
Hematologic Oncology